What is Viatris Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Viatris's interest expense for the
three
months ended in Mar. 2025 was $ -116 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2025 was $-527 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Viatris's Operating Income for the
three
months ended in Mar. 2025 was $ -9 Mil. Viatris's Interest Expense for the
three
months ended in Mar. 2025 was $ -116 Mil.
Viatris did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Viatris Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-527 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris (NAS:VTRS) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Viatris's Interest Expense for the
three
months ended in Mar. 2025 was $-116 Mil. Its
Operating Income
for the
three
months ended in Mar. 2025 was $-9 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2025 was $14,355 Mil.
Viatris's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as
| Viatris did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Viatris Business Description
Traded in Other Exchanges
Address
1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Executives
| Scott Andrew Smith |
director |
C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
| Paul Campbell |
officer: See Remarks |
BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL |
| Rajiv Malik |
director, officer: President |
BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL |
| Brian Roman |
officer: Global General Counsel |
1000 MYLAN BOULEVARD, CANONSBURG PA 15317 |
| Anthony Mauro |
officer: See Remarks |
BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL |
| Dillon Joellen Lyons |
director |
BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HARTFORDSHIRE X0 AL 109UL |
| Xiangyang (sean) Ni |
officer: President, Greater China |
1000 MYLAN BOULEVARD, CANONSBURG PA 15317 |
| Andrew Cuneo |
officer: See Remarks |
1000 MYLAN BOULEVARD, CANONSBURG PA 15317 |
| Harry Korman |
director |
BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL |
| Leo Frans Groothuis |
director |
1000 MYLAN BOULEVARD, CANONSBURG PA 15317 |
| Elisha W Finney |
director |
C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304 |
| Van Der Meer Mohr Pauline |
director |
1000 MYLAN BOULEVARD, CANONSBURG PA 15317 |
| Menassie Taddese |
officer: See Remarks |
1000 MYLAN BOULEVARD, CANONSBURG PA 15317 |
| Robert J Coury |
director, officer: Executive Chairman |
BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL |
| W Don Cornwell |
director |
|
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VTRS has been successfully added to your 